New imaging, AI, and manufacturing tools are finally making the microbiome druggable.
Source
- DCVC, Deep Tech Opportunities Report 2026 (opens in a new tab)5.3Published: 1 Jul 2026
Source thesis
Microbial communities are hard to observe, causally interpret and manufacture consistently as therapeutic products. The report discusses Spatial labeling, imaging and machine learning to map host-microbe interactions; Anaerobic manufacturing of defined live microbial mixtures; Investigational programs for cancer-treatment response, treatment-associated colitis and environmental enteric dysfunction. Examples cited: Kanvas Biosciences.